Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether–lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya  by Achieng, Angela O. et al.
lable at ScienceDirect
International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 92e99Contents lists avaiInternational Journal for Parasitology:
Drugs and Drug Resistance
journal homepage: www.elsevier .com/locate/ i jpddrTemporal trends in prevalence of Plasmodium falciparum molecular
markers selected for by artemetherelumefantrine treatment in pre-
ACT and post-ACT parasites in western Kenya
Angela O. Achieng a, Peninah Muiruri a, b, Luicer A. Ingasia a, Benjamin H. Opot a,
Dennis W. Juma a, Redemptah Yeda a, Bidii S. Ngalah a, c, Bernhards R. Ogutu a,
Ben Andagalu a, Hoseah M. Akala a, Edwin Kamau a, *
a Department of Emerging Infectious Diseases, United States Army Medical Research Unit-Kenya/Kenya Medical Research Institute, Kisumu, Kenya
b Department of Biochemistry, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
c Institute of Tropical Medicine and Infectious Diseases, College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenyaa r t i c l e i n f o
Article history:
Received 24 March 2015
Received in revised form
27 May 2015
Accepted 28 May 2015
Available online 29 June 2015
Keywords:
Artemetherelumefantrine
Drug-resistance
Western Kenya
Artemisinin-based combination therapies
Africa
Chloroquine
Molecular markers
Genetics* Corresponding author.
E-mail address: edwin.kamau.mil@mail.mil (E. Ka
http://dx.doi.org/10.1016/j.ijpddr.2015.05.005
2211-3207/Published by Elsevier Ltd on behalf of Aus
org/licenses/by-nc-nd/4.0/).a b s t r a c t
Artemetherelumefantrine (AL) became the ﬁrst-line treatment for uncomplicated malaria in Kenya in
2006. Studies have shown AL selects for SNPs in pfcrt and pfmdr1 genes in recurring parasites compared
to the baseline infections. The genotypes associated with AL selection are K76 in pfcrt and N86, 184F and
D1246 in pfmdr1. To assess the temporal change of these genotypes in western Kenya, 47 parasite isolates
collected before (pre-ACT; 1995e2003) and 745 after (post-ACT; 2008e2014) introduction of AL were
analyzed. In addition, the associations of parasite haplotype against the IC50 of artemether and lume-
fantrine, and clearance rates were determined. Parasite genomic DNA collected between 1995 and 2014
was analyzed by sequencing or PCR-based single-base extension on Sequenom MassARRAY. IC50s were
determined for a subset of the samples. One hundred eighteen samples from 2013 to 2014 were from an
efﬁcacy trial of which 68 had clearance half-lives. Data revealed there were signiﬁcant differences be-
tween pre-ACT and post-ACT genotypes at the four codons (chi-square analysis; p < 0.0001). The
prevalence of pfcrt K76 and N86 increased from 6.4% in 1995e1996 to 93.2% in 2014 and 0.0% in 2002
e2003 to 92.4% in 2014 respectively. Analysis of parasites carrying pure alleles of K þ NFD or T þ YYY
haplotypes revealed that 100.0% of the pre-ACT parasites carried T þ YYY and 99.3% of post-ACT parasites
carried K þ NFD. There was signiﬁcant correlation (p ¼ 0.04) between lumefantrine IC50 and poly-
morphism at pfmdr1 codon 184. There was no difference in parasite clearance half-lives based on genetic
haplotype proﬁles. This study shows there is a signiﬁcant change in parasite genotype, with key mo-
lecular determinants of AL selection almost reaching saturation. The implications of these ﬁndings are
not clear since AL remains highly efﬁcacious. However, there is need to closely monitor parasite geno-
typic, phenotypic and clinical dynamics in response to continued use of AL in western Kenya.
Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recent gains made in malaria control have relied on the sus-
tained efﬁcacy of artemisinin-based combination therapies (ACTs)
which is the recommended ﬁrst-line treatment for uncomplicated
Plasmodium falciparum malaria by the World Health Organization
(WHO). ACTs consist of a short-acting artemisinin componentmau).
tralian Society for Parasitology. Thiwhich rapidly reduces parasite biomass and results in consequent
rapid resolution of the symptoms (Na et al., 1994; Bethel et al., 1997;
White et al., 1999), and a long-acting partner drug (White et al.,
1999) essential in clearing residual parasitemia. Resistance to
ACTs is threatening malaria control and elimination efforts in
Southeast Asia (SEA) (Noedl et al., 2008; Dondorp et al., 2009;
WHO, 2014). However, ACTs remain highly efﬁcacious in sub-
Saharan Africa (SSA) with fast clearance half-lives (Ashley et al.,
2014; Zwang et al., 2014). Sensitive P. falciparum parasites are
cleared within 48 h in 95% of the patients post-ACTs treatment
based on smears (White, 2008) whereas resistant parasites ares is an open access article under the CC BY-NC-ND license (http://creativecommons.
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et al., 2009). The presence of parasites at 72 h is a good predictor of
subsequent treatment failure (Stepniewska et al., 2010). Mutations
in the P. falciparum K13-propeller domain have recently been
shown to be important determinants of artemisinin resistance in
SEA (Ariey et al., 2014; Ashley et al., 2014). However, the K13-
propeller region mutations recently described in SEA have not
been found in African parasites (Ashley et al., 2014; Conrad et al.,
2014; Kamau et al., 2014; Taylor et al., 2014) nor has there been
an association of K13 polymorphisms with parasite clearance half-
lives in African parasites (Ashley et al., 2014).
The most commonly used ACT in SSA is artemetherelumefan-
trine (AL) (WHO, 2013) which has been used as the ﬁrst-line
treatment for uncomplicated malaria in Kenya since 2006 (Amin
et al., 2007). In a recent study where individual patient data from
31 clinical trials was analyzed, the overall clinical efﬁcacy for pa-
tients treated with AL was shown to be 94.8%; 93.8% efﬁcacy in East
Africa and 96.2% in West Africa (Venkatesan et al., 2014). In Kenya,
AL efﬁcacy has remained >95% (Ogutu et al., 2014). Although AL
remains highly efﬁcacious and K13 polymorphisms are not asso-
ciated with reduced susceptibility to ACTs in SSA, AL is associated
with selection of single nucleotide polymorphisms (SNPs) in
P. falciparum chloroquine resistance transporter gene (pfcrt) and
P. falciparum multidrug resistance gene 1 (pfmdr1) in parasite re-
infections (Sisowath et al., 2005; Humphreys et al., 2007;
Sisowath et al., 2007, 2009). The genotype associated with the
parasite re-infection is the K76 in pfcrt and N86, 184F and D1246
(NFD) in the pfmdr1. Further, reduced susceptibility to lumefantrine
has also been linked to NFD and increase in the pfmdr1 copy
numbers (Lim et al., 2009; Some et al., 2010; Gadalla et al., 2011;
Malmberg et al., 2013a,b). Recent meta-analysis of clinical trials
data showed the presence of N86 allele and an increased pfmdr1
copy number were themost signiﬁcant independent risk factors for
recurrence of parasites in patients treated with AL (Venkatesan
et al., 2014). Monitoring the selection and emergence of these
markers presents a cost-effective method for detecting evidence of
declines in parasite susceptibility to AL and should be made routine
(Malmberg et al., 2013a,b; Venkatesan et al., 2014).
In 1998, sulphadoxineepyrimethamine (SP) replaced chloro-
quine as the ﬁrst-line treatment of uncomplicated malaria in Kenya
due to treatment failure and in 2006, SP was replaced with AL
(Shretta et al., 2000; Amin et al., 2007; Okiro et al., 2010). In both
instances, treatment failures were attributed to development of
drug resistance. The genotype associated with chloroquine resis-
tance is pfcrt 76T (Djimde et al., 2001), modulated by pfmdr1 86Y,
Y184 and 1246Y (YYY) (Reed et al., 2000; Babiker et al., 2001).
Interestingly, chloroquine resistant parasites are AL sensitive; i.e. AL
selects for chloroquine sensitive parasites. In this study, we set out
to analyze the temporal trends of parasite genotypes in pfcrt (codon
76) and pfmdr1 (codons 86, 184 and 1246) in parasite samples from
Kisumu County, western Kenya, collected before (1995e2003) and
after (2008e2014) introduction of AL, referred to as pre- and post-
ACT respectively. The 50% inhibition concentration (IC50) of arte-
mether and lumefantrine in ﬁeld isolates carrying combined pfcrt/
pfmdr1 haplotype K þ NFD were compared to those carrying
haplotype T þ YYY. Further, the association of parasite clearance
rates with these haplotypes was investigated.
2. Materials and methods
2.1. Samples
Samples used in this study were obtained from Kisumu County
in pre- and post-ACT periods. Forty seven pre-ACT parasite samples
were collected between 1995 and 2003 whereas 745 post-ACTparasites were collected between 2008 and 2014. Samples were
collected under protocols approved by the Ethical Review Com-
mittee of the Kenya Medical Research Institute (KEMRI), Nairobi,
Kenya and Walter Reed Army Institute of Research (WRAIR) Insti-
tutional Review Board, Silver Spring, MD. The pre-ACT and post-
ACT studies were conducted under approved study protocols
KEMRI-SSC 1330/WRAIR 1384 (Epidemiology of malaria and drug
sensitivity patterns in Kenya) and KEMRI-SSC 2518/WRAIR 1935
(In vivo and in vitro efﬁcacy of artemisinin combination therapy in
Kisumu County, western Kenya) respectively. KEMRI-SSC 2518/
WRAIR 1935 efﬁcacy study was conducted in Kombewa division,
which is in Kisumu County, in 2013e2014. In both studies, patients
presenting with uncomplicated malaria, aged between 6 months
and 65 years were consented. Eligibility criteria included:
measured temperature of 37.5 C, a history of fever within 24 h
prior to presentation, mono-infection with P. falciparum and a
baseline parasitemia of 2000e200,000 asexual parasites/mL. Per-
sons treated for malaria within the preceding 2 weeks were
excluded from the study. Written informed consent was obtained
from adult subjects (18 years of age) or legal guardians for sub-
jects <18 years of age. The presence of malaria was conﬁrmed by
microscopy and rapid diagnostic test (RDT; Parascreen®, Zephyr
Biomedicals, Verna Goa, India). Whole blood was collected and
aliquots preserved for analysis as speciﬁed in the study protocols.
For KEMRI-SSC 1330/WRAIR 1384 protocol, subjects were treated
with oral AL (Coartem) administered over three consecutive days, a
standard of care for P. falciparum malaria in Kenya. The ﬁrst dose
was observed by the study team and remaining doses were self-
administered at home. For KEMRI-SSC 2518/WRAIR 1935, subjects
were admitted at the study facility for approximately 3 days, until
two consecutive smear negative slides were obtained.
2.2. Pfcrt and Pfmdr1 genotyping
Genomic DNA was extracted from whole blood using QIAamp
Blood mini kit (Qiagen, Valencia, CA, USA) as recommended by the
manufacturer. Extracted DNA was stored appropriately until
analyzed. Pfcrt K76T and pfmdr1 N86Y, Y184F and D1246Y alleles
were determined by sequencing or PCR-based single-base extension
on Sequenom MassARRAY platform (Agena Biosciences, San Diego,
CA, USA) following manufacturer recommendations. Previously
published primers for pfcrt K76T (Djimde et al., 2001) and pfmdr1
SNPs (Vinayak et al., 2010) were used for PCR and sequencing an-
alyses. The ﬁnal concentration of PCR reactants were as follows:
0.5 mM each of the primers, 1 PCR buffer, 4 mM of magnesium
chloride (MgCl2), 0.02 Units of Taq polymerase,100 mM (25 mMeach)
of deoxynucleotides. After successfully amplifying the target re-
gions, the isolates were puriﬁed using Exosap-it® (Affymetrix, Santa
Clara, CA) as per the manufacturer's protocol. Sequencing of the
target regions was done on the 3500 xL ABI Genetic analyzer using
version 3.1 of the big dye terminator method (Applied Biosystems,
Foster City, CA). Contig assembly of the generated sequences was
performed using CLC Bio Workbench 6 and the sequences aligned
and analyzed using BioEdit version 7.1.3.0. All sequences were
compared against the pfcrt (Accession Number; XM_001348968)
and pfmdr1 (Accession Number; XM_001351751) 3D7 reference
sequence published in the NCBI database.
2.3. In vitro drug susceptibility testing
The drugs used for the in vitro testing were artemether and
lumefantrine which were supplied by the Division of Experimental
Therapeutics of the WRAIR. Parasites were maintained in contin-
uous culture as previously described (Trager and Jensen, 1976).
SYBR Green I- based drug sensitivity assay was used for the in vitro
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Johnson et al., 2007; Rason et al., 2008). P. falciparum parasites in
continuous culture attaining 3%e8% parasitemia were adjusted to
2% hematocrit and 1% parasitemia. Blood samples with >1% para-
sitemia were adjusted to 1% parasitemia at 2% hematocrit, and
those with 1% parasitemia were used unadjusted at 2%
hematocrit.
Drugs were prepared in 5 mL of 99.5% dimethyl sulfoxide to
attain 5 mg/mL which were lowered to starting concentrations of
690 nM for AT and 378 nM for LU. This was followed by serial
dilution across 10-concentrations ranging from (in nM) AT 670 to
0.65 and LU 378 to 0.37. For drug assaying, 3.2 mL of this drug was
coated on to 384-well plates. The assay was initiated by the addi-
tion of 100 mL reconstituted parasite components added to drug
coated plates and incubated at 37 C as previously described (Bacon
et al., 2007; Johnson et al., 2007; Rason et al., 2008). The assay was
terminated after 72 h by adding 100 mL of lysis buffer containing
SYBRGreen I (1 ﬁnal concentration) directly to the plates and kept
at room temperature in the dark for 24 h. Parasite replication in-
hibition was quantiﬁed by measuring the per-well relative ﬂuo-
rescence units (RFU) of SYBR Green I dye using the Tecan Genios
Plus® with excitation and emission wavelengths of 485 nm and
535 nm. The IC50 values for each drug were calculated as previously
described (Johnson et al., 2007).
2.4. Statistical analysis
Changes in prevalence of pfcrt and pfmdr1 individual SNPs and
the combined haplotype pre- and post-ACT were analyzed using
chi-square test for proportions and logistic regression with year
included as a continuous covariate respectively. The odds ratios
(OR) analysis was done using STATA version 11 (Stata, College Sta-
tion, TX); OR were used to calculate the relative change of parasite
genotype and the IC50s per year. Chi-square analysis was used to
compare change in the prevalence of genotypes. This was done
using the Prism program (version 5.0.2; GraphPad Software, Inc.,
San Diego, CA). The IC50 estimates were expressed as medians with
interquartile ranges (IQR). Further, IC50 data for isolates with the
different genetic polymorphism in pfcrt and pfmdr1were compared
by using nonparametric tests (1-way analysis of variance, Krus-
kaleWallis test with Dunn's multiple comparison post test). Asso-
ciations between IC50 estimates and genetic markers were
considered signiﬁcant when p-value < 0.05.
3. Results
3.1. Prevalence of SNPs in pre- and post-ACT parasites
A total of 792 ﬁeld isolates collected from the study sites be-
tween 1995 and 2014 were successfully analyzed. There were 47
pre-ACT (1995e2003) samples and 745 post-ACT (2008e2014)
samples analyzed; the pre-ACT sample size was signiﬁcantly
smaller than the post-ACT. For the post-ACT samples,118were from
an efﬁcacy study, of which 68 had parasite clearance half-life data
and were used in subsequent analysis. Four SNPs were genotyped:
Pfcrt 76 and pfmdr1 86, 184 and 1246. Analysis was performed for
pre-ACT and post-ACT parasites, revealing statistically signiﬁcant
difference between pre- and post-ACT genotypes at the four codons
(chi-square analysis; p < 0.0001). Data revealed that the mean
prevalence of thewild-type allele in pfcrt codon 76 (K76) in pre-ACT
parasites was 10.4% and 61.7% post-ACT, whereas the mean preva-
lence for the mutant allele in pfcrt codon 76 (76T) in pre-ACT par-
asites was 62.2% and 28.5% in post-ACT. In pre-ACT parasites, 27.4%
carried the mixed genotype whereas in post-ACT, 9.8% carried the
mixed genotype. Further analysis revealed K76 prevalence waslowest in 1995e1996 at 6.4% and highest in 2014 at 93.2% whereas
76T was highest in 2002e2003 at 85.7% and lowest in 2014 at 2.3%.
For the wild-type allele in pfmdr1 codon 86 (N86), the mean
prevalence in pre-ACT parasites was 16.7% and 73.0% in post-ACT
whereas the mean prevalence for the mutant allele in pfmdr1
codon 86 (86Y) in pre-ACT parasites was 62.8% and 14.9% in post-
ACT. The prevalence of mixed genotype was 20.5% and 11.4% in
pre- and post-ACT parasites respectively. Further, data revealed
N86 prevalence was lowest in 2002e2003 at 0.0% and highest in
2014 at 92.4%, whereas 86Ywas highest in 2002e2003 at 92.3% and
lowest in 2014 at 0.7%.
The mean prevalence of the wild-type allele in pfmdr1 codon
184 (Y184) in pre-ACT parasites was 11.6% and 35.0% in post-ACT
whereas the mean prevalence for the mutant allele in pfmdr1
codon 184 (184F) in pre-ACT parasites was 67.8% and 40.8% in post-
ACT. The prevalence of the mixed genotype was 17.1% and 24.2% in
pre- and post-ACT parasites respectively. Further, data revealed
Y184 prevalence was lowest in 2002e2003 at 8.3% and highest in
2008 at 50.0% whereas prevalence of 184F was highest in
2002e2003 at 83.3% and lowest in 2008 at 30.0%.
The mean prevalence of the wild-type allele in pfmdr1 codon
1246 (D1246) in pre-ACT parasites was 40.0% and 83.5% in post-ACT
whereas themean prevalence for themutant allele in pfmdr1 codon
1246 (1246Y) in pre-ACT parasites was 43.4% and 13.8% in post-ACT.
The prevalence of mixed genotype was 16.7% and 2.7% in pre- and
post-ACT parasites respectively. Further, data revealed D1246
prevalence was lowest in 2002e2003 at 20.0% and highest in
2008 at 100.0% whereas prevalence of 1246Y was highest in
2002e2003 at 66.7% and lowest in 2013 at 5.5%.
3.2. Prevalence of K þ NFD and T þ YYY haplotypes
Parasite haplotypes at codon 76 in pfcrt and codons 86, 184 and
1246 in pfmdr1 were evaluated. Data in all the four codons were
obtained in 499 samples (70.2%) where 28 were pre-ACT and 471
post-ACT. Further, we analyzed K þ NFD and T þ YYY haplotypes.
There were 142 parasite samples carrying K þ NFD or T þ YYY
haplotype; 132 were K þ NFD and 10 were T þ YYY (Table 1).
3.3. Temporal trends of SNPs in pfcrt and pfmdr1 genes
Fig. 1 shows the temporal trend of SNPs in pfcrt and pfmdr1
genes from 1995 to 2014. The prevalence of pfcrt K76 increased
from 6.4% in 1995e1996 to 93.2% in 2014 (Fig. 2). Therewas a steady
increase over the 20-year period from 10.4% in pre-ACT parasites to
61.7% in post-ACT (yearly OR¼ 0.67 [95% CI 0.60 0.74; p < 0.001]).
The mutant allele, pfcrt 76T was highest in 2002e2003 at 85.7%,
decreasing to 2.3% in 2014. In 1995e1996, the majority of the par-
asites carried mixed alleles (54.8%) whereas in 2014, only 4.9%
carried mixed genotype. In post-ACT, parasites collected in 2010,
2011 and 2012 had low prevalence of the pfcrt K76, with 2011
having the lowest prevalence at 37.0%. Interestingly, in 2013 and
2014, the prevalence of pfcrt K76 increased signiﬁcantly to more
than twice the previous year (2012), reaching 92.9% in 2014.
The wild-type allele in pfmdr1 codon 86 increased from 33.3% in
1995e1996 to 92.4% in 2014 (Fig. 2). This incrementwas steady over
the 20-year period from 16.7% in pre-ACT parasites to 72.0% in post-
ACT (yearly OR¼ 0.76 [95% CI 0.72 0.82; p < 0.0001]). Themutant
allele, pfcrt 86Y was highest in 2002e2003 at 92.3%, decreasing to
0.7% in 2014; there was no single parasite carrying the wild-type
allele in 2002e2003. The highest percentage of the mixed alleles
was in found 1995e1996 parasites at 33.3%, decreasing to 6.9% in
2014. The wild-type allele in pfmdr1 codon 184 increased from
14.8% in 1995e1996 to 31.4% in 2014. The highest prevalence of
pfmdr1 Y184 was in 2008 at 50.0% which was followed by a
Table 1
Number of parasites carrying K þ NFD versus T þ YYY haplotype from 1995 to 2014.
1995e1996
n (%)
2002e2003
n (%)
2008
n (%)
2009
n (%)
2010
n (%)
2011
n (%)
2012
n (%)
2013
n (%)
2014
n (%)
K þ NFD 0 (0.0) 0 (0.0) 3 (23.1) 6 (14.3) 3 (4.4) 0 (0.0) 10 (19.0) 29 (16.6) 81 (27.7)
T þ YYY 2 (6.5) 7 (20.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0) 0 (0.0)
Fig. 1. The prevalence of SNP in the pfcrt and pfmdr1 genes in the pre- and the post-ACTs parasite samples.
Fig. 2. The temporal trends of the pfcrt K76 and pfmdr1 N86 alleles in the pre- and the
post-ACT periods (1995e2014). The percent prevalence of parasite samples carrying
either K76 or N86 genotype over the years. The arrow indicates the post-ACT period.
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the mutant allele pfmdr1 184F was in 2002e2003 at 83.3% and
lowest in 2008 at 30.0%. There was a steady increase of the mixed
genotype at codon 184 from 20.0% in 2008 to 33.1% in 2014. With
exception of 2008, the prevalence of pfmdr1 184F remained higher
than pfmdr1 Y184 in all post-ACT parasites (yearly OR ¼ 1.1 [95% CI
1.04  1.16; p < 0.001]).
The wild-type allele in pfmdr1 codon 1246 increased from 60.0%
in 1995e1996 to 81.6% in 2014 (yearly OR ¼ 0.87 [95% CI
0.83 0.92; p< 0.001]). The prevalence of themutant allele, pfmdr1
1246Y was highest in 2002e2003 at 66.7% and lowest in 2008 at
0.0%. However, the prevalence of the mutant allele rebounded back
in 2009 at 24.0% but steadily declined over time reaching 6.9% in
2014. There were no mixed genotypes between 2008 and 2012.3.4. Temporal trends of K þ NFD and T þ YYY haplotypes in pre-
and post-ACT parasites
Of the 28 pre-ACT parasite samples with complete genotype
data at codon pfcrt 76 and codons pfmdr186, 184 and 1246, analysis
of parasite samples carrying pure alleles of K þ NFD or T þ YYY
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carried the Tþ YYY (n¼ 9). In post-ACT parasite samples, of the 471
parasite samples successfully analyzed at all the codons, 28.2%
(n ¼ 133) of the parasite samples carried K þ NFD haplotype
whereas only 0.2% (n ¼ 1) carried T þ YYY haplotype; the single
T þ YYY haplotype in post-ACT parasite samples was present in
2012 (Table 1). K þ NYD haplotype was not present in pre-ACT
parasite samples but appeared in the post-ACT parasite samples,
increasing signiﬁcantly in 2013e2014; there were 3 parasite sam-
ples in 2009, 2 in 2011, 41 in 2013 and 67 in 2014 carrying this
haplotype. Other haplotypes of interest analyzed include those
carrying the mixed allele at pfcrt 76 and pure single alleles at
pfmdr1 84, 186 and 1246. For example, there was one pre-ACT
parasite sample that carried K/T þ NFD and eight in post-ACT
parasite samples, and two parasite samples in 2009 that carried
K/T þ YYY. Mixed alleles at all the four codons were present only in
pre-ACT parasite samples.
3.5. Associations of in vitro sensitivity with pfcrt and pfmdr1
polymorphisms
Artemether and lumefantrine IC50 values for the two reference
strains, 3D7 andW2, were established and used as internal controls
in subsequent experiments. The IC50 datawas obtained for a total of
187 ﬁeld isolates with genotype data at any one of the four codons.
The proﬁle for in vitro sensitivities per genetic polymorphism in all
the four codons was assessed. At each codon, the correlation of the
IC50s (for artemether and lumefantrine) were done for parasites
carrying the wild-type, mutant or mixed alleles. For the pfcrt codon
76, the median (interquartile range [IQR]) of artemether IC50 for
parasites carrying K76, 76T or K76T alleles were 3.2 nM
(1.6e6.4 nM), 3.5 nM (2.4e9.5 nM) and 5.0 nM (2.6e12.5 nM),
respectively. Although K76T had a slightly higher median IC50, the
difference did not reach statistical signiﬁcance (1-way ANOVA,
KruskaleWallis test p ¼ 0.06). Similarly, the difference in IC50s for
lumefantrine between the three different pfcrt genotypes did not
reach statistical difference (p ¼ 0.29). Analysis of the pfmdr1
revealed there was signiﬁcant correlation (1-way ANOVA, Krus-
kaleWallis test p ¼ 0.04) between lumefantrine IC50 and poly-
morphism at codon 184. The median (IQR) lumefantrine IC50s for
parasites carrying Y184, 184F or Y184F alleles were 25.8
(11.2e43.2), 27.0 (11.9e59.5) and 12.0 (4.8e39.3), respectively.
Dunn's multiple comparison test revealed the signiﬁcance was
between IC50s for parasites carrying 184F vs. Y184F. There was no
other genotype in pfmdr1 that showed any correlation with either
artemether or lumefantrine.
3.6. Associations of parasite clearance rates with pfcrt and pfmdr1
polymorphisms
Clearance half-lives were obtained for the 68 subjects with
complete parasite haplotype proﬁles. Five different parasite
haplotype proﬁles were analyzed including K þ NFD, K þ NYD,
K þ N Y/F D, K þ N Y/F D/Y and all other proﬁles combined that did
not fall to any of the indicated haplotype proﬁles. There was no
difference in the parasite clearance half-lives based on genetic
haplotype proﬁles (1-way ANOVA, KruskaleWallis test, p ¼ 0.61).
4. Discussion
The data shows a dramatic change in the prevalence of anti-
malarial molecular markers associatedwith changes in chloroquine
drug pressure and deployment of AL in western Kenya. The sig-
niﬁcant changes are in the prevalence of the wild-type alleles in
pfcrt codon 76, and pfmdr1 codons 86 and 1246 between pre-ACTand the post-ACT era which coincided with withdrawal of chloro-
quine and the introduction of AL. The pfcrt K76 and pfmdr1 N86
alleles had the most dramatic increase in prevalence reaching to
more than 92% in the post-ACT period from low points of 6.4% and
0.0% respectively in the pre-ACT period. Conversely, pfcrt 76T and
pfmdr1 86Y prevalence dramatically decreased 38- and 128-fold
respectively from the highest point in the pre-ACT period to the
lowest point in the post-ACT period. The prevalence of mixed ge-
notypes in these two codons decreased as well. The pfmdr1 D1246
also had dramatic change, increasing to a prevalence of 87.2% in
2013. Conversely, the prevalence of pfmdr11246Y decreased to 5.5%
in 2013. The mixed genotype decreased from the pre-ACT period to
the post-ACT period. The prevalence of pfmdr1 Y184 allele and the
mixed genotype increased in the post-ACT parasites compared to
the pre-ACT parasites. Interestingly, haplotype analysis revealed
the pre-ACT parasites carried only T þ YYY haplotype whereas the
post-ACT parasites, with exception of one parasite (1 out of 133),
carried the K þ NFD haplotype. Of interest was the K þ NYD (wild-
type in all the four alleles) which appeared in the post-ACT para-
sites, increasing dramatically in 2013 and 2014. Our data also
revealed that there was a signiﬁcant correlation between lume-
fantrine IC50 with polymorphisms at pfmdr1 codon 184. However,
there was no association between parasite clearance rates with
polymorphisms at codons in pfcrt or pfmdr1 genes.
In line with previous studies (Kublin et al., 2003; Laufer et al.,
2010; Eyase et al., 2013; Okombo et al., 2014) we have shown
there was selection of the pfcrt K76 after change of drug policy.
Removal of chloroquine drug pressure results in resurgence of
chloroquine sensitive parasite population. In Malawi, the ree-
mergence of chloroquine-sensitive P. falciparum malaria parasites
reached 100% in less than 10 years after chloroquine was replaced
with SP (Kublin et al., 2003). In our study, there was evidence of
dramatic resurgence (p < 0.001) of the pfcrt K76 in 2008, 2 years
after introduction of AL and close to 10 years after withdraw of
chloroquine. However, in 2002e2003, about 5 years after with-
drawal of chloroquine and introduction of SP, the pfcrt K76 had not
dramatically resurged. In the Kenyan coastal region, studies have
revealed a signiﬁcant decrease of the pfcrt 76T after the withdrawal
of chloroquine. In samples analyzed from Kiliﬁ (which is in the
coastal region of Kenya), the pfcrt 76T decreased from 94% to 63%
from 1993 to 2006 and in a study conducted in Tiwi which is also at
the Kenyan coast, the pfcrt 76T decreased from 88% to 64% from
1999 to 2008 (Mwai et al., 2009; Mang'era et al., 2012). In a more
recent study which also used samples from Kiliﬁ, there was a more
drastic change in the pfcrt 76T from 96% in 1999 to 15% in 2012/
2013 (Okombo et al., 2014). In our study, we saw a more dramatic
drop of the pfcrt 76T from a high of 85.7% in 2002/2003 to 2.3% in
2014. This is the lowest reported prevalence of the pfcrt 76T in
Kenya. At the same time, Okombo et al. (2014) reported signiﬁcance
resurgence of the pfcrt K76 in Kiliﬁ from 38% in 1995 to 81.7% in
2012/2013. In our study, the pfcrt K76 resurged from 6.4% to 92.9%
in 2014. There is obvious signiﬁcant resurgence of the pfcrt K76 in
Kenyan parasites after the withdrawal of chloroquine. The rate of
change in the pfcrt K76 is not related to transmission intensity as
the changes are almost identical between western and coastal re-
gions of Kenya which have different transmission and disease
endemicity. A recent study from western Kenya showed a direc-
tional selection of the pfcrt K76 after treatment of patients with AL
(Henriques et al., 2014). Our data demonstrates that after the
removal of chloroquine pressure on the parasite population, there
was a loss of the pfcrt 76T genotype but at a slow rate with the
introduction of SP. AL was adopted as the ﬁrst-line treatment in
Kenya in 2006 (Amin et al., 2007). The frequency of the pfcrt 76T
allele decreased after the introduction of AL but it is not until the
2013/2014 time-frame that there was a dramatic loss of the pfcrt
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K76 allele by AL.
A recent pooled analysis from clinical trials showed patients
infected with parasites carrying the pfmdr1 N86 allele and/or
increased the pfmdr1 copy number (as independent risk factors)
were at a signiﬁcantly greater risk of AL treatment failure than
those whose parasites carried the 86Y allele or a single copy of the
pfmdr1 (Venkatesan et al., 2014). In a recent study where we
analyzed the presence and distribution of the copy number varia-
tion of the pfmdr1 gene in the pre- and the post-ACT parasites,
seven of eight parasite samples with multiple pfmdr1 gene copy
number were the post-ACT (Ngala et al., 2015). We also showed
that the post-ACT parasites had signiﬁcantly higher pfmdr1 gene
copy number compared to the pre-ACT parasites (p ¼ 0.0002).
There was an overlap in the parasite samples analyzed in this study
and the Ngalah et al. (2015) study. Although the pfmdr1 gene
ampliﬁcation is rarely reported in African parasites (Uhlemann
et al., 2005; Holmgren et al., 2006), a recent efﬁcacy study
showed ampliﬁcation of the pfmdr1 gene contributes to recurrent
P. falciparum parasitemia following AL treatment (Gadalla et al.,
2011). In this study, we have shown dramatic increase of the
pfmdr1 N86 from 0.0% in 2002/2003 to reaching over 92% in 2014
and the pfmdr1 86Y decreasing to less than 1% in 2014. This data
presents evidence of strong selection of the pfmdr1 N86 allele, as
well as increased pfmdr1 gene copy number in the post-ACT para-
sites which is rarely reported in African parasites. The increased
prevalence of the N86 allele and the pfmdr1 gene copy number are
the most signiﬁcant independent risk factors for recurrence of
parasites in patients treated with AL (Venkatesan et al., 2014).
Although adequate clinical and parasitological response to ACTs
remain high in western Kenya (Ogutu et al., 2014), data suggest
there is underlying selection of parasites taking place (Henriques
et al., 2014) which might result in decreased parasite susceptibil-
ity to AL. Indeed, re-infecting parasites carrying the pfmdr1 N86
have been shown to withstand lumefantrine 35-fold higher
compared to those carrying the pfmdr1 86Y (Malmberg et al.,
2013a). To the best of our knowledge, our data shows the highest
prevalence of the pfmdr1 N86 and increase of pfmdr1 gene copy
number that has ever been reported for western Kenya parasites.
In line with previous studies (Sisowath et al., 2007; Malmberg
et al., 2013a,b), we showed there was also a signiﬁcant increase of
the pfmdr1 D1246 in the post-ACT parasites compared to the pre-
ACT parasites. In the post-ACT parasites, the pfmdr1 184F allele
trend remained relatively constant but the mixed allele, pfmdr1
Y184F signiﬁcantly increased over time. Interestingly, when we
analyzed the association of the in vitro parasites sensitivity with the
pfcrt and pfmdr1 polymorphisms, only polymorphisms at the
pfmdr1 codon 184 showed signiﬁcant association with lumefan-
trine IC50. The clinical relevance of this ﬁnding is not clear but
provides a basis to support closemonitoring of parasite clearance in
western Kenya since development of resistance to antimalarials is a
dynamic process. In a study that assessed patient lumefantrine
drug level and its association with the pfmdr1 polymorphisms, the
inﬂuence of polymorphisms at codon 184 was not clear since par-
asites carrying the Y184 allele, which is considered to be “sensi-
tive”, were able to withstand high drug levels (Malmberg et al.
2013a).
The haplotype K þ NFD has been shown to appear following AL
treatment (Sisowath et al., 2005, 2007, 2009). In line with previous
studies (Malmberg et al., 2013a,b; Okombo et al., 2014) K þ NFD
haplotype increased signiﬁcantly in the post-ACT period. The
haplotype T þ YYY appeared only in the pre-ACT parasite samples
and not in the post-ACT. Of interest was the appearance of the
K þ NYD haplotype which was not present in pre-ACT parasite
samples but appeared and increased signiﬁcantly longitudinally inthe post-ACT parasite samples. This is also in line with the recent
study by (Okombo et al., 2014) where they showed signiﬁcant in-
crease of the K þ NYD haplotype over time. Malmberg et al.
(2013a,b) showed a trend of decreasing lumefantrine susceptibil-
ity in the order of NFD, NYD, YYY, and YYD. Our data present evi-
dence that strong selection of these haplotypes is taking place in
western Kenya due to use of AL. Interestingly, recent studies sug-
gested selection for the NFD haplotype is exerted by the artemisinin
component of the ACTs (Conrad et al., 2014; Henriques et al., 2014).
Clear evidence has shown these selected haplotypes have
decreased susceptibility to lumefantrine (Malmberg et al., 2013a,b)
but no such evidence has been presented for artemisinin compo-
nent for the ACTs. Whether selection of these genotypes will lead to
reduced susceptibility to AL remains to be seen but calls for close
monitoring.
Although polymorphisms at the pfmdr1 codons 86, 184, 1034,
1042, 1246 are associated with altered sensitivity to artemisinins
and meﬂoquine in SEA, the key determinant has been shown to be
the copy number variation (Cowman et al., 1994; Price et al., 1999;
Duraisingh et al., 2000; Price et al., 2004; Sidhu et al., 2005; Picot
et al., 2009; Muhamad et al., 2011). Further, the discovery of mu-
tations in K13-propeller in SEA but not in African parasites shows
the multigenetic nature of artemisinin resistance in different parts
of the world. AL and other ACTs remain highly efﬁcacious in SSA
including western Kenya (Ogutu et al., 2014; Venkatesan et al.,
2014). Whether selection of haplotype K þ NFD or K þ NYD sig-
niﬁes apparent selection of AL resistant parasite is yet to be
conﬁrmed. Even with the emergence and spread of ACTs resistant
parasites in SEA, ACTs remain the ﬁrst-line treatment in this region.
The pfcrt K76 allele and pfmdr1 N86 might soon reach saturation at
100% prevalence in western Kenya. Further, for the ﬁrst-time in
western Kenya, we have shown the prevalence of pfmdr1 copy
number is on the rise. The apparent recent increase in these mo-
lecular markers should be a cause to rethink the issue with the
deployment of ﬁrst-line treatment of uncomplicated malaria.
Although in vivo efﬁcacy of AL remains >95%, the malaria com-
munity should start thinking of strategies of deploying other ACTs
that are currently available to ensure a longer useful therapeutic
lifespan before other new molecules are available in the market.
With the prevalence of pfcrt K76 allelewell above 90%, a clear re-
emergence of chloroquine-sensitive P. falciparum malaria in west-
ern Kenya, there is need to evaluate the role of chloroquine or
compounds in the same class in the treatment of malaria. This is
supported by the current molecular data that unambiguously show
genetic polymorphisms in pfcrt and pfmdr1 genes are changing in
favor of chloroquine sensitivity.
Based on our ﬁndings and data from other studies (Kublin et al.,
2003; Laufer et al., 2010; Gadalla et al., 2011; Eyase et al., 2013;
Malmberg et al., 2013a,b; Henriques et al., 2014; Ogutu et al.,
2014; Okombo et al., 2014; Venkatesan et al., 2014), more studies
are required to determine the genotypic or phenotypic parasite
characteristics that are directly associated with artemisinin resis-
tance. Further, studies on how to mitigate the emergence and
spread of parasites that are resistance to ACTs are critical in SSA
where majority of the deaths due to malaria occur.
5. Conclusion
We have shown signiﬁcant increase in polymorphisms at key
codons in the pfcrt and pfmdr1 genes that are selected for by AL and
decrease of these key codons with the withdrawal of chloroquine.
This is exempliﬁed by the high prevalence of the KþNFD haplotype
which although associated with reduced susceptibility to AL, is
generally linked to increased susceptibility to chloroquine and
amodiaquine (Humphreys et al., 2007). There was no association
A.O. Achieng et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 92e9998between parasite clearance rates and the pfcrt and pfmdr1 poly-
morphisms. The ﬁndings call for close monitoring of parasite
genotypic, phenotypic and clinical dynamics in response to current
ﬁrst-line treatment inwestern Kenya. Having been the ﬁrst focus of
chloroquine resistance in Africa (Fogh et al., 1979), western Kenya
will be crucial in informing the next steps on the deployment of
ﬁrst-line treatment of uncomplicated malaria in the possible future
era of attenuated response of artemisinin in SSA.
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